Skip to content
← All treatment topics

TREATMENT READING

Uterine Sarcoma

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

33 sections
  1. Treatment Option Overview for Uterine Sarcoma
  2. Treatment of Stage I Uterine Sarcoma
  3. Treatment Options for Stage I Uterine Sarcoma
  4. Treatment of Stage II Uterine Sarcoma
  5. Treatment Options for Stage II Uterine Sarcoma
  6. Treatment of Stage III Uterine Sarcoma
  7. Treatment Options for Stage III Uterine Sarcoma
  8. Treatment of Stage IV Uterine Sarcoma
  9. Treatment Options for Stage IV Uterine Sarcoma
  10. Treatment of Recurrent Uterine Sarcoma
  11. Treatment Options for Recurrent Uterine Sarcoma
  12. Past treatment with radiation therapy to the pelvis can increase the risk of uterine sarcoma.
  13. Certain factors affect prognosis (chance of recovery) and treatment options.
  14. Uterine sarcoma may be diagnosed, staged, and treated in the same surgery.
  15. Uterine sarcoma can recur (come back) after it has been treated.
  16. Treatment Option Overview
  17. Key Points
  18. There are different types of treatment for patients with uterine sarcoma.
  19. The following types of treatment are used:
  20. Surgery
  21. Radiation therapy
  22. Chemotherapy
  23. Hormone therapy
  24. New types of treatment are being tested in clinical trials.
  25. Treatment for uterine sarcoma may cause side effects.
  26. Patients may want to think about taking part in a clinical trial.
  27. Patients can enter clinical trials before, during, or after starting their cancer treatment.
  28. Follow-up care may be needed.
  29. Treatment of Stage I Uterine Sarcoma
  30. Treatment of Stage II Uterine Sarcoma
  31. Treatment of Stage III Uterine Sarcoma
  32. Treatment of Stage IV Uterine Sarcoma
  33. Treatment of Recurrent Uterine Sarcoma

Health professional

Treatment Option Overview for Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Surgery is often the principal means of diagnosis and is the primary treatment for all patients with uterine sarcoma. If the diagnosis is known, the extent of surgery is planned according to the stage of the tumor. Hysterectomy is usually performed when a uterine malignancy is suspected, except for rare instances when preservation of the uterus in a young patient is deemed safe for the type of cancer (e.g., a totally confined low-grade leiomyosarcoma in a woman who desires to retain childbearing potential). Medically suitable patients with the preoperative diagnosis of uterine sarcoma are considered candidates for abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy. Cytologic washings are obtained from the pelvis and abdomen. Thorough examination of the diaphragm, omentum, and upper abdomen is performed.

There is no firm evidence from a prospective study that adjuvant chemotherapy or radiation therapy is of benefit for patients with uterine sarcoma.[1] In one Gynecologic Oncology Group (GOG) study, the use of adjuvant doxorubicin did not alter the survival rate of patients with resected stage I or stage II uterine sarcomas; however, interpretation of these results is difficult because this study included some patients who received radiation and three types of uterine sarcomas that have variable responses to doxorubicin.[1][Level of evidence A1] Because the risk of disease recurrence is high, even with localized presentations, many physicians have considered the use of adjuvant chemotherapy or radiation therapy.[2] Another GOG study (GOG-0150 [NCT00002546]) addressed radiation therapy versus adjuvant chemotherapy.[3]

Sources: 1 · 1 · Level of evidence A1 · 2 · GOG-0150 · 3

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Stage I Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Health professional · Treatment of Stage I Uterine Sarcoma

Treatment Options for Stage I Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Treatment options for stage I uterine sarcoma include:

Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy).

Surgery plus pelvic radiation therapy.

Surgery plus adjuvant chemotherapy.

Surgery plus adjuvant radiation therapy.

A nonrandomized Gynecologic Oncology Group study examined the effect of pelvic radiation therapy on patients with stage I and II carcinosarcomas. Patients who had pelvic radiation therapy had a significant reduction in tumor recurrences within the radiation treatment field but no alteration in survival.[1] A large nonrandomized study demonstrated improved survival and a lower local failure rate in patients with mixed mullerian tumors following postoperative external and intracavitary radiation therapy.[2] One nonrandomized study that predominantly included patients with carcinosarcomas showed that adjuvant chemotherapy with cisplatin and doxorubicin benefitted participants.[3]

Sources: 1 · 2 · 3

Health professional

Treatment of Stage II Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Health professional · Treatment of Stage II Uterine Sarcoma

Treatment Options for Stage II Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Treatment options for stage II uterine sarcoma include:

Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy).

Surgery plus pelvic radiation therapy.

Surgery plus adjuvant chemotherapy.

Surgery plus adjuvant radiation therapy.

A nonrandomized Gynecologic Oncology Group study examined the effect of pelvic radiation therapy on patients with stage I and II carcinosarcomas. Patients who had pelvic radiation therapy had a significant reduction in tumor recurrences within the radiation treatment field but no alteration in survival.[1] One nonrandomized study that predominantly included patients with carcinosarcomas showed that adjuvant chemotherapy with cisplatin and doxorubicin benefitted participants.[2]

Sources: 1 · 2

Health professional

Treatment of Stage III Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Health professional · Treatment of Stage III Uterine Sarcoma

Treatment Options for Stage III Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Treatment options for stage III uterine sarcoma include:

Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and periaortic selective lymphadenectomy, and resection of all gross tumor).

Surgery plus pelvic radiation therapy (under clinical evaluation).

Surgery plus adjuvant chemotherapy (under clinical evaluation).

Phase II chemotherapy studies by the Gynecologic Oncology Group have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide.[1,2] These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. In patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas [3] and a 17.2% partial response rate in patients with leiomyosarcomas.[2]

Sources: 1 · 2 · 3 · 2

GOG-108 was a randomized trial that examined the use of ifosfamide with or without cisplatin as first-line therapy for patients with measurable advanced or recurrent carcinosarcomas. Patients in the combination arm had a higher response rate (54% vs. 34%) and longer progression-free survival (PFS) (6 months vs. 4 months). However, patients did not have a significant improvement in survival (9 months vs. 8 months).[4][Level of evidence A1] The follow-up GOG-0161 study [NCT00003128] used 3-day ifosfamide regimens (instead of the more toxic 5-day regimen in the preceding study) given alone or in combination with paclitaxel (with filgrastim starting on day 4).[5] The combination was superior in response rates (45% vs. 29%), PFS (8.4 months vs. 5.8 months), and overall survival (13.5 months vs. 8.4 months). The hazard ratio for death favored the combination (0.69; 95% confidence interval, 0.49–0.97).[5][Level of evidence A1] In this study, 52% of 179 evaluable patients had recurrent disease, 18% had stage III disease, and 30% had stage IV disease. In addition, imbalances were present in the sites of disease and in the use of prior radiation therapy, and 30 patients were excluded for wrong pathology.

Sources: 4 · Level of evidence A1 · GOG-0161 · 5 · 5 · Level of evidence A1

A role for chemotherapy as an adjuvant to surgery has not been established.

Health professional

Treatment of Stage IV Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Health professional · Treatment of Stage IV Uterine Sarcoma

Treatment Options for Stage IV Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

There is currently no standard therapy for patients with stage IV disease. These patients should enroll in an ongoing clinical trial.

Phase II chemotherapy studies by the Gynecologic Oncology Group have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide.[1,2] These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. In patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas,[2] a 33% response rate in patients with endometrial stromal cell sarcomas,[3], and a 17.2% partial response rate in patients with leiomyosarcomas.[4] Doxorubicin in combination with dacarbazine or cyclophosphamide is no more active than doxorubicin alone for advanced disease.[5,6] Cisplatin has activity as first-line therapy and minimal activity as second-line therapy for patients with carcinosarcomas, but cisplatin is inactive as first- or second-line therapy for patients with leiomyosarcomas.[1,7]

Sources: 1 · 2 · 2 · 3 · 4 · 5 · 6 · 1 · 7

GOG-108 was a randomized trial that examined the use of ifosfamide with or without cisplatin as first-line therapy for patients with measurable advanced or recurrent carcinosarcomas. Patients in the combination arm had a higher response rate (54% vs. 34%) and longer progression-free survival (PFS) (6 months vs. 4 months). However, patients did not have a significant improvement in survival (9 months vs. 8 months).[8][Level of evidence A1] The follow-up GOG-0161 study [NCT00003128] used 3-day ifosfamide regimens (instead of the more toxic 5-day regimen in the preceding study) given alone or in combination with paclitaxel (with filgrastim starting on day 4).[9] The combination was superior in response rates (45% vs. 29%), PFS (8.4 months vs. 5.8 months), and overall survival (13.5 months vs. 8.4 months). The hazard ratio for death favored the combination (0.69; 95% confidence interval, 0.49–0.97).[9][Level of evidence A1] In this study, 52% of 179 evaluable patients had recurrent disease, 18% had stage III disease, and 30% had stage IV disease. In addition, imbalances were present in the sites of disease and in the use of prior radiation therapy, and 30 patients were excluded for wrong pathology.

Sources: 8 · Level of evidence A1 · GOG-0161 · 9 · 9 · Level of evidence A1

Health professional

Treatment of Recurrent Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

Health professional · Treatment of Recurrent Uterine Sarcoma

Treatment Options for Recurrent Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: December 17, 2024. Captured 2026-09-09.

There is currently no standard therapy for patients with recurrent disease. These patients should enroll in an ongoing clinical trial.

Phase II chemotherapy studies by the Gynecologic Oncology Group have documented some antitumor activity for cisplatin, doxorubicin, and ifosfamide.[1,2] These studies have also documented differences in response leading to separate trials for patients with carcinosarcomas and leiomyosarcomas. In patients previously untreated with chemotherapy, ifosfamide had a 32.2% response rate in patients with carcinosarcomas,[2] a 33% response rate in patients with endometrial stromal cell sarcomas,[3] and a 17.2% partial response rate in patients with leiomyosarcomas.[4] Doxorubicin in combination with dacarbazine or cyclophosphamide is no more active than doxorubicin alone for recurrent disease.[5,6] Cisplatin has activity as first-line therapy and minimal activity as second-line therapy for patients with carcinosarcomas, but cisplatin is inactive as first- or second-line therapy for patients with leiomyosarcomas.[1,7] A regimen of gemcitabine plus docetaxel had a 53% response rate in patients with unresectable leiomyosarcomas and is undergoing further study.[8]

Sources: 1 · 2 · 2 · 3 · 4 · 5 · 6 · 1 · 7 · 8

GOG-108 was a randomized trial that examined the use of ifosfamide with or without cisplatin as first-line therapy for patients with measurable advanced or recurrent carcinosarcomas. Patients in the combination arm had a higher response rate (54% vs. 34%) and longer progression-free survival (PFS) (6 months vs. 4 months). However, patients did not have a significant improvement in survival (9 months vs. 8 months).[9][Level of evidence A1] The follow-up GOG-0161 study [NCT00003128] used 3-day ifosfamide regimens (instead of the more toxic 5-day regimen in the preceding study) given alone or in combination with paclitaxel (with filgrastim starting on day 4).[10] The combination was superior in response rates (45% vs. 29%), PFS (8.4 months vs. 5.8 months), and overall survival (13.5 months vs. 8.4 months). The hazard ratio for death favored the combination (0.69; 95% confidence interval, 0.49–0.97).[10][Level of evidence A1] In this study, 52% of 179 evaluable patients had recurrent disease, 18% had stage III disease, and 30% had stage IV disease. In addition, imbalances were present in the sites of disease and in the use of prior radiation therapy, and 30 patients were excluded for wrong pathology.

Sources: 9 · Level of evidence A1 · GOG-0161 · 10 · 10 · Level of evidence A1

Radiation therapy may be an effective method of palliative care for patients with carcinosarcoma who have localized recurrence in the pelvis confirmed by computed tomography. Phase I and II clinical trials are appropriate for patients who have disease recurrence with distant metastasis and are unresponsive to first-line phase II trials. High-dose progesterone hormone therapy may be of some benefit to patients with low-grade stromal sarcoma.[11]

Sources: 11

For patients · General Information About Uterine Sarcoma

Past treatment with radiation therapy to the pelvis can increase the risk of uterine sarcoma.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Anything that increases a person's chance of getting a disease is called a risk factor. Not every person with one or more of these risk factors will develop an uterine sarcoma, and it will develop in some people who don't have any known risk factors. Talk with your doctor if you think you may be at risk. Risk factors for uterine sarcoma include:

Sources: risk factor

Past treatment with radiation therapy to the pelvis.

Sources: radiation therapy

Treatment with tamoxifen for breast cancer. If you are taking this drug, have a pelvic exam every year and report any vaginal bleeding (other than menstrual bleeding) as soon as possible.

Sources: tamoxifen · breast cancer · drug · pelvic exam · vaginal · menstrual

For patients · General Information About Uterine Sarcoma

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

The prognosis and treatment options depend on:

Sources: prognosis

The stage of the cancer.

Sources: stage

The type and size of the tumor.

The patient's general health.

Whether the cancer has just been diagnosed or has recurred (come back).

Sources: diagnosed · recurred

For patients · Stages of Uterine Sarcoma

Uterine sarcoma may be diagnosed, staged, and treated in the same surgery.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Surgery is used to diagnose, stage, and treat uterine sarcoma. During this surgery, the doctor removes as much of the cancer as possible. The following procedures may be used to diagnose, stage, and treat uterine sarcoma:

Sources: Surgery · diagnose · uterine sarcoma

Laparotomy: A surgical procedure in which an incision (cut) is made in the wall of the abdomen to check the inside of the abdomen for signs of disease. The size of the incision depends on the reason the laparotomy is being done. Sometimes organs are removed or tissue samples are taken and checked under a microscope for signs of disease.

Sources: Laparotomy · surgical · incision

Abdominal and pelvic washings: A procedure in which a saline solution is placed into the abdominal and pelvic body cavities. After a short time, the fluid is removed and viewed under a microscope to check for cancer cells.

Sources: Abdominal · pelvic · saline · cavities · fluid

Total abdominal hysterectomy: A surgical procedure to remove the uterus and cervix through a large incision (cut) in the abdomen.

Sources: Total abdominal hysterectomy · cervix

Bilateral salpingo-oophorectomy: Surgery to remove both ovaries and both fallopian tubes.

Sources: Bilateral salpingo-oophorectomy · ovaries

Lymphadenectomy: A surgical procedure in which lymph nodes are removed and checked under a microscope for signs of cancer. For a regional lymphadenectomy, some of the lymph nodes in the tumor area are removed. For a radical lymphadenectomy, most or all of the lymph nodes in the tumor area are removed. This procedure is also called lymph node dissection.

Sources: Lymphadenectomy · lymph nodes · regional lymphadenectomy · radical lymphadenectomy

Treatment in addition to surgery may be given, as described in the Treatment Option Overview section of this summary.

Sources: Treatment Option Overview

For patients · Stages of Uterine Sarcoma

Uterine sarcoma can recur (come back) after it has been treated.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

The cancer may come back in the uterus, the pelvis, or in other parts of the body.

For patients

Treatment Option Overview

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

There are different types of treatment for patients with uterine sarcoma.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Radiation therapy

Chemotherapy

Hormone therapy

New types of treatment are being tested in clinical trials.

Treatment for uterine sarcoma may cause side effects.

Patients may want to think about taking part in a clinical trial.

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for patients with uterine sarcoma.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Different types of treatments are available for patients with uterine sarcoma. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. A treatment clinical trial is a research study meant to help improve current treatments or obtain information on new treatments for patients with cancer. When clinical trials show that a new treatment is better than the standard treatment, the new treatment may become the standard treatment. Patients may want to think about taking part in a clinical trial. Some clinical trials are open only to patients who have not started treatment.

Sources: uterine sarcoma · standard · clinical trials · research study · cancer

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Surgery is the most common treatment for uterine sarcoma, as described in the Stages of Uterine Sarcoma section of this summary.

Sources: Surgery · Stages of Uterine Sarcoma

After the doctor removes all the cancer that can be seen at the time of the surgery, some patients may be given chemotherapy or radiation therapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: chemotherapy · radiation therapy · cells · adjuvant therapy

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high energy x-rays or other types of radiation to kill cancer cells or keep them from growing. There are two types of radiation therapy:

Sources: x-rays · radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: External radiation therapy

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer.

Sources: Internal radiation therapy · radioactive · seeds · catheters

The way the radiation therapy is given depends on the type and stage of the cancer being treated. External and internal radiation therapy are used to treat uterine sarcoma, and may also be used as palliative therapy to relieve symptoms and improve quality of life.

Sources: stage · palliative therapy · symptoms · quality of life

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Chemotherapy is a cancer treatment that uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. When chemotherapy is taken by mouth or injected into a vein or muscle, the drugs enter the bloodstream and can reach cancer cells throughout the body (systemic chemotherapy).

Sources: drugs · injected · vein · systemic chemotherapy

For patients · Treatment Option Overview / The following types of treatment are used:

Hormone therapy

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Hormone therapy is a cancer treatment that removes hormones or blocks their action and stops cancer cells from growing. Hormones are substances produced by glands in the body and circulated in the bloodstream. Some hormones can cause certain cancers to grow. If tests show the cancer cells have places where hormones can attach (receptors), drugs, surgery, or radiation therapy is used to reduce the production of hormones or block them from working.

Sources: Hormone therapy · hormones · glands · receptors

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Information about clinical trials is available from the NCI website.

Sources: NCI website

For patients · Treatment Option Overview

Treatment for uterine sarcoma may cause side effects.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Patients may want to think about taking part in a clinical trial.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For some patients, taking part in a clinical trial may be the best treatment choice. Clinical trials are part of the cancer research process. Clinical trials are done to find out if new cancer treatments are safe and effective or better than the standard treatment.

Sources: clinical trial · standard treatment

Many of today's standard treatments for cancer are based on earlier clinical trials. Patients who take part in a clinical trial may receive the standard treatment or be among the first to receive a new treatment.

Patients who take part in clinical trials also help improve the way cancer will be treated in the future. Even when clinical trials do not lead to effective new treatments, they often answer important questions and help move research forward.

For patients · Treatment Option Overview

Patients can enter clinical trials before, during, or after starting their cancer treatment.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

Some clinical trials only include patients who have not yet received treatment. Other trials test treatments for patients whose cancer has not gotten better. There are also clinical trials that test new ways to stop cancer from recurring (coming back) or reduce the side effects of cancer treatment.

Sources: side effects

Clinical trials are taking place in many parts of the country. Information about clinical trials supported by NCI can be found on NCI’s clinical trials search webpage. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

For patients

Treatment of Stage I Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For information about the treatments listed below, visit the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stage I leiomyosarcoma of the uterus, stage I endometrial stromal sarcoma, and stage I adenosarcoma of the uterus may include:

Sources: stage I leiomyosarcoma of the uterus · stage I endometrial stromal sarcoma · stage I adenosarcoma of the uterus

Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy).

Sources: Surgery · total abdominal hysterectomy · bilateral salpingo-oophorectomy · lymphadenectomy

Surgery followed by radiation therapy to the pelvis.

Sources: radiation therapy · pelvis

Surgery followed by chemotherapy.

Sources: chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage II Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For information about the treatments listed below, visit the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stage II leiomyosarcoma of the uterus, stage II endometrial stromal sarcoma, and stage II adenosarcoma of the uterus may include:

Sources: stage II leiomyosarcoma of the uterus · stage II endometrial stromal sarcoma · stage II adenosarcoma of the uterus

Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and lymphadenectomy).

Sources: Surgery · total abdominal hysterectomy · bilateral salpingo-oophorectomy · lymphadenectomy

Surgery followed by radiation therapy to the pelvis.

Sources: radiation therapy · pelvis

Surgery followed by chemotherapy.

Sources: chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For information about the treatments listed below, visit the Treatment Option Overview section.

Sources: Treatment Option Overview

Treatment of stage III leiomyosarcoma of the uterus, stage III endometrial stromal sarcoma, and stage III adenosarcoma of the uterus may include:

Sources: stage III leiomyosarcoma of the uterus · stage III endometrial stromal sarcoma · stage III adenosarcoma of the uterus

Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, lymphadenectomy, and removal of all other tissue where tumor is found).

Sources: Surgery · total abdominal hysterectomy · bilateral salpingo-oophorectomy · lymphadenectomy · tissue

A clinical trial of surgery followed by radiation therapy to the pelvis.

Sources: clinical trial · radiation therapy · pelvis

A clinical trial of surgery followed by chemotherapy.

Sources: chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage IV Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

There is no standard treatment for patients with stage IV leiomyosarcoma of the uterus, stage IV endometrial stromal sarcoma, or stage IV adenosarcoma of the uterus. Treatment may include a clinical trial using chemotherapy.

Sources: standard treatment · stage IV leiomyosarcoma of the uterus · stage IV endometrial stromal sarcoma · stage IV adenosarcoma of the uterus · clinical trial · chemotherapy

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Recurrent Uterine Sarcoma

Source: Uterine Sarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: March 14, 2025. Captured 2026-09-09.

For information about the treatments listed below, visit the Treatment Option Overview section.

Sources: Treatment Option Overview

There is no standard treatment for recurrent uterine sarcoma. Treatment may include a clinical trial using chemotherapy.

Sources: standard treatment · recurrent · uterine sarcoma · clinical trial · chemotherapy

For patients with recurrent carcinosarcoma (a certain type of tumor), treatment may include:

Sources: carcinosarcoma · tumor

Radiation therapy as palliative therapy to relieve symptoms (such as pain, nausea, or bowel problems) and improve the quality of life.

Sources: Radiation therapy · palliative therapy · symptoms · nausea · bowel · quality of life

Hormone therapy.

Sources: Hormone therapy

A clinical trial of a new treatment.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

NCT00002546 · COMPLETED · phase3

Sarcoma

ClinicalTrials.gov record

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

NCT00075400 · COMPLETED · phase2

Recurrent Uterine Sarcoma, Uterine Carcinosarcoma

ClinicalTrials.gov record

Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer

NCT00238121 · COMPLETED · phase2

Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma

ClinicalTrials.gov record

Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma

NCT00856050 · COMPLETED · phase2

Leiomyosarcoma

ClinicalTrials.gov record

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

NCT01012297 · TERMINATED · phase3

Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma,...

ClinicalTrials.gov record

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

NCT01061606 · TERMINATED · phase2

Recurrent Uterine Sarcoma, Uterine Carcinosarcoma

ClinicalTrials.gov record

Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer

NCT01367301 · TERMINATED · na

Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB...

ClinicalTrials.gov record

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

NCT01533207 · TERMINATED · phase3

Stage I Uterine Sarcoma AJCC v7, Uterine Corpus Leiomyosarcoma

ClinicalTrials.gov record

Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery

NCT01958580 · TERMINATED · na

Stage IA Uterine Sarcoma, Stage IB Uterine Sarcoma, Stage IC Uterine Sarcoma, Stage IIA Uterine Sarcoma, Stage IIB Uterine Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB...

ClinicalTrials.gov record

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

NCT02428192 · COMPLETED · phase2

Metastatic Leiomyosarcoma, Unresectable Leiomyosarcoma, Uterine Corpus Leiomyosarcoma

ClinicalTrials.gov record

Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary

NCT03206177 · COMPLETED · phase1

Carcinosarcoma, Ovarian

ClinicalTrials.gov record

Vorinostat (SAHA) in Uterine Sarcoma

NCT03509207 · TERMINATED · phase2

Leiomyosarcoma, Endometrial Stromal Tumors, Carcinosarcomas Uterine

ClinicalTrials.gov record

Disease and treatment settings

recurrent Uterine Sarcoma

Disease and treatment setting

Treatment of Recurrent Uterine Sarcoma

Stage I Uterine Sarcoma

Disease and treatment setting

Treatment of Stage I Uterine Sarcoma

Stage II Uterine Sarcoma

Disease and treatment setting

Treatment of Stage II Uterine Sarcoma

Stage III Uterine Sarcoma

Disease and treatment setting

Treatment of Stage III Uterine Sarcoma

Stage IV Uterine Sarcoma

Disease and treatment setting

Treatment of Stage IV Uterine Sarcoma

Uterine Sarcoma

Disease and treatment setting

Uterine Sarcoma